| Prev Close | 158.71 |
| Open | 159.10 |
| Day Low/High | 157.26 / 159.10 |
| 52 Wk Low/High | 72.67 / 160.03 |
| Volume | 3.71M |
Alexion Pharmaceuticals, Inc. (ALXN)
157.74
0.97
0.61
NASDAQ
| Exchange | NASDAQ |
| Shares Outstanding | 218.72B |
| Market Cap | 34.27B |
| P/E Ratio | 36.61 |
| Div & Yield | N.A. (N.A) |
Latest News
2 Potential Acquisition Targets as Biotech Deal Activity Picks Up
BioXcel Therapeutics and Avadel Pharmaceuticals would make good additions to the portfolios of larger drug companies.
Alexion Is Reaching New Heights
Shares of this biotech company look like a good opportunity.
I Liked These 4 Stocks Before Earnings, Now I Like Them Even More
Here's an update of our investment themes on these companies.
On the Lookout for Revenue Rebounds Among Covid-Dinged Biotechs
The early stages of the pandemic hurt sales at many biotech companies, but there are signs that revenue streams are picking back up.
Alexion Pharmaceuticals Just Made an Upside Breakout: Here's What to Do
Let's check out the charts of this drug maker that raised its full-year 2020 revenue guidance.
3 Covid-Proof Plays Not Named Amazon or Apple
Tutor Perini, Beazer Homes and Alexion Pharmaceuticals all turned in solid results in the face of the pandemic.
Strength in Alexion Pharmaceuticals May Be Temporary
Be cautious about ALXN in the short-run.
Keeping Sane, the Profitable Way: How I'm Playing This Market
I continue to shuttle new money into the market on declines using buy-write option strategies.
4 Biotech Stocks I'm Targeting Now
I've stayed primarily to those names that have plenty of cash on the balance sheet and should be just fine once saner heads prevail.
2 Healthcare Stocks That Look Like Bargains Relative to Their Growth Prospects
Alexion Pharmaceuticals and Lantheus Holdings are interesting names at current trading levels.
Alexion Pharmaceuticals Does Not Look Boston Strong
Charts of the Boston-based biotech to do not provide a compelling case to buy the stock.
Big Biotech Receives Some Needed Shots in the Arm
Biogen, Novartis and Bristol-Myers Squibb are among the drugmakers that gave investors reasons for cheer on Tuesday.
6 Top Biopharmaceutical Stock Picks You Should Know About
The aging population is creating a massive tailwind for companies that provide cutting-edge health care.
Here Are Several Promising Rare Disease Stocks
These small biotech concerns are undervalued.
I'm Unapologetically Overweight in These 2 Sectors
The two are homebuilding and biotech, and there are stocks within those sectors where I've parked my money.
3 Biotech Plays That Would Work as Covered Calls
The SPDR S&P Biotech ETF, Alexion Pharmaceuticals and BioMarin Pharmaceuticals set up nicely for this options strategy.
A Sagging Drugmaker and Lagging Pet Health Name Both Worth Looks
Alexion Pharmaceuticals and Elanco Animal Health have seen their shares go to the dogs of late, but still offer reasons for portfolio consideration.
Otezla Price Under Microscope -- but Look Closely and It Checks Out
Sure, Celgene, in its tie-up with Bristol-Myers Squibb, had to sell to meet merger requirements, but look at the future pay off for Amgen.
M&A Appetite in Pharma Has Proved Potent: Chart of the Day
With total deals trending toward hundreds of billions, investors may be eager to bet on who's next to be acquired.
Amgen Adds Celgene's Otezla to Bolster Pipeline at Pricey Valuation
Amgen is finally making an expected splash out of its cash pile, but questions are abounding about the cost paid for Celgene's Otezla.
A Pair of Rare Disease Biotech Concerns Worth a Good Look
Alexion Pharmaceuticals is a solid company that is the subject of acquisition rumors and Amicus Therapeutics has a key drug off to a strong start.
5 Favorites for Biotech Stock Buyers
For those with a long-term horizon, here are some top picks.
A Handful of Small Biotechs That Make for Merger Chatter
The names include a veterinary drug concern plus companies with successful drugs on the market.
A Six-Pack of Biotech Best Bets
Ironically, some experts now see biotech as a safe haven as the sector remains unaffected by trade wars and other global headwinds.
Roche Deal for Spark Therapeutics Shows Biotech M&A Spark Hasn't Died
Acquisition deals for biotech companies at the start of 2019 are giving the sector a nice boost; here are other names that could be merger candidates.
